Sarilumab (Serbian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Sarilumab" in Serbian language version.
refsWebsite
Global rank
Serbian rank
1st place
1st place
3,257th place
1,641st place
low place
low place
low place
low place
179th place
200th place
719th place
468th place
ama-assn.org
- „Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab” (PDF). ama-assn.org. American Medical Association. Архивирано из оригинала
(PDF) 29. 09. 2012. г. Приступљено 18. 03. 2020.
doi.org
- Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM; et al. (2007). „"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial".”. Annals of the Rheumatic Diseases. 76 (5): 840—847. PMC 5530335
. PMID 27856432. doi:10.1136/annrheumdis-2016-210310.. - Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. (jun 2015). „Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study”. Arthritis & Rheumatology. 67 (6): 1424—37. PMID 25733246. doi:10.1002/art.39093.
drugs.com
- Drugs.com: Sarilumab Монографија. Accessed 18. 3. 2020
europa.eu
ema.europa.eu
- „Kevzara: Authorisation details”. European Medicines Agency. Архивирано из оригинала 27. 09. 2017. г. Приступљено 18. 3. 2020.
- „Kevzara: EPAR – Product Information” (PDF). European Medicines Agency. 26. 9. 2017. Архивирано из оригинала (PDF) 18. 06. 2018. г. Приступљено 18. 03. 2020.
medscape.com
- „Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment”. www.medscape.com 17. 3. 2020. Архивирано из оригинала 28. 04. 2020. г. Приступљено 18. 3. 2020.
modernmedicine.com
formularyjournal.modernmedicine.com
- Walker T. „Sarilumab effective in broad range of RA patients: Study”. Formulary Watch. Архивирано из оригинала 21. 11. 2015. г.
nih.gov
ncbi.nlm.nih.gov
- Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM; et al. (2007). „"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial".”. Annals of the Rheumatic Diseases. 76 (5): 840—847. PMC 5530335 . PMID 27856432. doi:10.1136/annrheumdis-2016-210310..
- Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. (jun 2015). „Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study”. Arthritis & Rheumatology. 67 (6): 1424—37. PMID 25733246. doi:10.1002/art.39093.
sanofi.com
en.sanofi.com
- „Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013” (PDF). Архивирано из оригинала (PDF) 19. 01. 2017. г. Приступљено 18. 03. 2020.
stanford.edu
med.stanford.edu
- „More Information”. Sarcoidosis Program (на језику: енглески). Архивирано из оригинала 9. 8. 2019. г. Приступљено 18. 3. 2020.
web.archive.org
- „Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab” (PDF). ama-assn.org. American Medical Association. Архивирано из оригинала (PDF) 29. 09. 2012. г. Приступљено 18. 03. 2020.
- „Kevzara: Authorisation details”. European Medicines Agency. Архивирано из оригинала 27. 09. 2017. г. Приступљено 18. 3. 2020.
- „Kevzara: EPAR – Product Information” (PDF). European Medicines Agency. 26. 9. 2017. Архивирано из оригинала (PDF) 18. 06. 2018. г. Приступљено 18. 03. 2020.
- „Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013” (PDF). Архивирано из оригинала (PDF) 19. 01. 2017. г. Приступљено 18. 03. 2020.
- Walker T. „Sarilumab effective in broad range of RA patients: Study”. Formulary Watch. Архивирано из оригинала 21. 11. 2015. г.
- „More Information”. Sarcoidosis Program (на језику: енглески). Архивирано из оригинала 9. 8. 2019. г. Приступљено 18. 3. 2020.
- „Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment”. www.medscape.com 17. 3. 2020. Архивирано из оригинала 28. 04. 2020. г. Приступљено 18. 3. 2020.